About US
Contact us
-
GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be doneBig Pharma companies routinely say they're working on boosting drug access worldwide, but, every other year, the Access to Medicine Foundation publicly calls out shortcomings in their efforts. Whi2022/11/17
-
COVID-19 tracker: Rebounds can occur regardless of treatment with Pfizer's Paxlovid, study findsA study testing rebounds in COVID-19 patients found that symptoms can return regardless of treatment with Paxlovid. Meanwhile, GeNuero and NanoViricidesare aiming to join the COVID-19 tre2022/11/15
-
Ardelyx FDA docs portend another showdown at this week's expert hearing on kidney disease prospectThe FDA's rejection of Ardelyx’s chronic kidney disease prospect last summer drew a rebuke from the company and analysts. But as an FDA panel of outside experts gathers to re-assess the drug on Wedne2022/11/15
-
GSK's Zejula FDA oncology AdComm canceled, leaving ovarian cancer nod in Schrodinger's boxThe FDA has decided it no longer needs input from external experts on an ovarian cancer indication for GSK’s Zejula. The oncologic drugs advisory committe2022/11/10
-
Plastics reborn: Inside Novo Nordisk's pre-filled pen recycling pilotThese days, Novo Nordisk is reincarnating many of its spent insulin pens as office furniture like chairs and lamps. It’s an increasinglycommon fatefor the company’s usedinjection devicesunder Novo2022/11/10
-
NICE signs off on Merck's Keytruda for early-stage triple negative breast cancerMonths after offeringMerck’s Keytrudarestricted coverage for previously untreated metastatic triple-negative breast cancer (TNBC), England’s drug cost watchdog has signed off on the drug’s use agains2022/11/8
-
Moderna's Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study saysIt’s been nearly two years since Moderna’s COVID-19 vaccine made its debut in the U.S., but research on the shot is far from over. Now, a new study has flagged higher risks of heart inflammation asso2022/11/8
-
SK bioscience plans global expansion push focused on vaccine manufacturing, gene therapy and moreAmid a global expansion push, SK bioscience has unveiled agrowth strategyfocused on broadeningits reach in vaccine manufacturing and R&D. Going forward, the company plans to focus on respondin2022/11/4
-
Moderna slashes billions from its sales forecast after a quarter of 'pain points'When Modernareacheda deal with the European Commission to delay some shipments of its COVID-19 vaccine to 2023, the company wasn’t certain how the development would affectsales projections for the sh2022/11/4
-
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapiesThe high cost of gene therapies has proved a sticking point for the personalized medicines in recent years, most notably prompting bluebird bio to withdraw its blood disorder treatment Zynteglo in Eu2022/11/2